Source link : https://newshealth.biz/health-news/adjuvant-cemiplimab-improves-disease-free-survival-in-high-risk-cutaneous-scc/
(MedPage Today) — CHICAGO — Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients at high risk of recurrence of cutaneous squamous-cell carcinoma (SCC), a phase III randomized trial… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115862 Author : Publish date : 2025-06-02 18:52:00 Copyright for syndicated content belongs to the linked Source.
The post Adjuvant Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous SCC first appeared on News Health.
—-
Author : News Health
Publish date : 2025-06-02 18:52:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8